Clinical Trials Logo

Clinical Trial Summary

The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training


Related Conditions & MeSH terms


NCT number NCT00122330
Study type Interventional
Source Alexion Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date October 2004
Completion date January 2006

See also
  Status Clinical Trial Phase
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00867932 - Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 4
Completed NCT00721864 - The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) N/A
Completed NCT00152139 - Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 3
Active, not recruiting NCT01642979 - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Phase 2
Active, not recruiting NCT01760096 - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Phase 2
Completed NCT00618969 - Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Phase 2
Completed NCT00098280 - Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Phase 3
Completed NCT00122304 - Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Phase 3
Recruiting NCT01224483 - Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients N/A
Active, not recruiting NCT00315419 - Identifying Characteristics of Bone Marrow Failure Syndromes N/A
Approved for marketing NCT00438789 - The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Phase 3